No Data
No Data
Fujian Wanchen Biotechnology Group Co., Ltd.'s (SZSE:300972) Subdued P/S Might Signal An Opportunity
When close to half the companies operating in the Food industry in China have price-to-sales ratios (or "P/S") above 1.4x, you may consider Fujian Wanchen Biotechnology Group Co., Ltd. (SZSE:300972) a
Be Wary Of Fujian Wanchen Biotechnology Group (SZSE:300972) And Its Returns On Capital
Did you know there are some financial metrics that can provide clues of a potential multi-bagger? Firstly, we'd want to identify a growing return on capital employed (ROCE) and then alongside that, a
Snack discount leader's profit inflection point has arrived | Insight Research
Wanchen Group's net profit for the third quarter was positive, and the net interest rate increased for four consecutive quarters.
Wanchen Group (300972.SZ) announced first-quarter results, net profit of 6.2382 million yuan, a decrease of 88.15%
According to the Zhitong Finance App, Wanchen Group (300972.SZ) released its report for the first quarter of 2024. The company's revenue was 4.83 billion yuan, an increase of 534.03% over the previous year. Net profit attributable to shareholders of listed companies was 6.2382 million yuan, a year-on-year decrease of 88.15%. Net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 1.98,800 yuan, a year-on-year decrease of 96.17%. Basic earnings per share were $0.0388.
Fujian Wanchen Biotechnology Group Co., Ltd. (SZSE:300972) Just Reported Full-Year Earnings: Have Analysts Changed Their Mind On The Stock?
Investors in Fujian Wanchen Biotechnology Group Co., Ltd. (SZSE:300972) had a good week, as its shares rose 9.7% to close at CN¥27.50 following the release of its full-year results. It was a mod
Wanchen Group (300972.SZ) announced its 2023 annual results, changing profit to loss to 82.965 million yuan
Wanchen Group (300972.SZ) released its 2023 annual report. The company's revenue was 9.294 billion...
No Data